IL138022A0 - High affinity humanized anti-cea monoclonal antibodies - Google Patents
High affinity humanized anti-cea monoclonal antibodiesInfo
- Publication number
- IL138022A0 IL138022A0 IL13802298A IL13802298A IL138022A0 IL 138022 A0 IL138022 A0 IL 138022A0 IL 13802298 A IL13802298 A IL 13802298A IL 13802298 A IL13802298 A IL 13802298A IL 138022 A0 IL138022 A0 IL 138022A0
- Authority
- IL
- Israel
- Prior art keywords
- monoclonal antibodies
- high affinity
- humanized anti
- cea monoclonal
- affinity humanized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6853—Carcino-embryonic antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1048—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57565—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1998/003680 WO1999043817A1 (fr) | 1998-02-25 | 1998-02-25 | Anticorps monoclonaux anti-ace humanises et faisant preuve d'une grande affinite |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL138022A0 true IL138022A0 (en) | 2001-10-31 |
Family
ID=22266464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13802298A IL138022A0 (en) | 1998-02-25 | 1998-02-25 | High affinity humanized anti-cea monoclonal antibodies |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1056859A1 (fr) |
| JP (1) | JP2002504372A (fr) |
| AU (1) | AU752494B2 (fr) |
| CA (1) | CA2321947A1 (fr) |
| IL (1) | IL138022A0 (fr) |
| NO (1) | NO20004251L (fr) |
| WO (1) | WO1999043817A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003025565A2 (fr) * | 2001-09-21 | 2003-03-27 | Caprion Pharmaceuticals Inc. | Preparation de membranes plasmiques fortement purifiees |
| CA2609142C (fr) | 2005-05-27 | 2016-02-09 | Fondazione Centro San Raffaele Del Monte Tabor | Vecteurs geniques therapeutiques comprenant des sequences cibles de microarn |
| PE20141017A1 (es) * | 2011-03-02 | 2014-08-25 | Roche Glycart Ag | Anticuerpos del cea |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| CN111533805B (zh) * | 2016-12-04 | 2022-02-08 | 深圳市国创纳米抗体技术有限公司 | 一种抗癌胚抗原的高亲和力纳米抗体及其应用 |
| CN113906053B (zh) | 2019-06-26 | 2022-10-25 | 江苏恒瑞医药股份有限公司 | 抗cea抗体及其应用 |
| CA3188867A1 (fr) | 2020-08-20 | 2022-02-24 | Xueyin Wang | Compositions et methodes de traitement de cancers positifs a ceacam |
| IL300500A (en) | 2020-08-20 | 2023-04-01 | A2 Biotherapeutics Inc | Preparations and methods for the treatment of mesothelin positive cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| US5472693A (en) * | 1993-02-16 | 1995-12-05 | The Dow Chemical Company | Family of anti-carcinoembryonic antigen chimeric antibodies |
| US5874540A (en) * | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| AU719513B2 (en) * | 1996-05-04 | 2000-05-11 | Astrazeneca Ab | Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system |
-
1998
- 1998-02-25 WO PCT/US1998/003680 patent/WO1999043817A1/fr not_active Ceased
- 1998-02-25 IL IL13802298A patent/IL138022A0/xx unknown
- 1998-02-25 EP EP98907630A patent/EP1056859A1/fr not_active Withdrawn
- 1998-02-25 AU AU63388/98A patent/AU752494B2/en not_active Ceased
- 1998-02-25 JP JP2000533557A patent/JP2002504372A/ja active Pending
- 1998-02-25 CA CA002321947A patent/CA2321947A1/fr not_active Abandoned
-
2000
- 2000-08-24 NO NO20004251A patent/NO20004251L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999043817A1 (fr) | 1999-09-02 |
| NO20004251L (no) | 2000-10-24 |
| AU6338898A (en) | 1999-09-15 |
| CA2321947A1 (fr) | 1999-09-02 |
| EP1056859A1 (fr) | 2000-12-06 |
| NO20004251D0 (no) | 2000-08-24 |
| AU752494B2 (en) | 2002-09-19 |
| JP2002504372A (ja) | 2002-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL128406A0 (en) | Monoclonal antibodies | |
| PL311926A1 (en) | Anti-alphav-integrinic monoclonal antibodies | |
| EP1073464A4 (fr) | Anticorps monoclonaux presentant une immunogenicite reduite | |
| IL115232A0 (en) | Monoclonal antibodies against colon carcinoma-associated antigens | |
| AU1462300A (en) | Human pan-hcv human monoclonal antibodies | |
| DK1516629T3 (da) | Humaniseret anti-CD-11a antibodies | |
| AU2559799A (en) | Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same | |
| AU1687500A (en) | Antihuman vegf monoclonal antibody | |
| IL147517A0 (en) | Monoclonal antibodies and immunoassay utilizing the same | |
| AU6702998A (en) | Anti-alphabeta3 humanized monoclonal antibodies | |
| AU4441799A (en) | Monoclonal antibodies that recognize antigens associated with tumor metastasis | |
| HUP0103573A3 (en) | Antithrombotic agent and humanized anti-von willebrand factor monoclonal antibody | |
| GB9608626D0 (en) | Hepatitis b monoclonal antibodies | |
| AU7072998A (en) | Immunoassays using anti-allotypic monoclonal antibodies | |
| EP0578515A3 (fr) | Anticorps monoclonaux humanisés. | |
| IL138022A0 (en) | High affinity humanized anti-cea monoclonal antibodies | |
| GB9718911D0 (en) | Monoclonal antibodies | |
| AU2596397A (en) | Monoclonal antibody that detects apoptotic antigen | |
| ZA951113B (en) | Tumor assosiated monoclonal antibody 123av16 | |
| GB9721432D0 (en) | Improved production of antibodies through the use of antigen antibody complexes | |
| EP1106701A4 (fr) | Anticorps monoclonal agissant contre la trypsine canine | |
| AP9801381A0 (en) | Anti-human mp52 monoclonal antibody | |
| EP0654532A4 (fr) | Anticorps monoclonal antimucoglycoproteine. | |
| GB9615027D0 (en) | Monoclonal antibodies | |
| AU7320998A (en) | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |